Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France

References

• Roman E, Smith AG. Epidemiology of lymphomas. Histopathology. 2011;58(1):4–14.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–1403.
   PubMed Web of Science ®Google Scholar
• Chihara D, Nastoupil LJ, Williams JN, et al. New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy. Expert Rev Anticancer Ther. 2015;15(5):531–544.
   PubMed Web of Science ®Google Scholar
• Monnereau A, Uhry Z, Bossard N, et al. Survie des personnes atteintes de cancer en France métropolitaine, 1989-2013. Partie 2 – Hémopathies malignes [Survival of people with cancer in metropolitan France, 1989-2013. Part 2 - Malignant hemopathies]. Saint-Maurice: Institute for Public Health Surveillance; 2016.
   Google Scholar
• Institut Universitaire du Cancer de Toulouse. Référentiel régional. Traitement des LYMPHOMES de l’ADULTES [University Cancer Institute of Toulouse. Regional guidelines. Treatment of ADULT LYMPHOMAS]. [cited 2018 Jan]. Available from: https://www.onco-occitanie.fr/system/files/2019-04/R%C3%A9f%C3%A9rentiel_Lymphome_Juillet2018.pdf.
   Google Scholar
• Ansell SM. Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc. 2015;90(11):1574–1583.
   PubMed Web of Science ®Google Scholar
• Ansell SM. Non-hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc. 2015;90(8):1152–1163.
   PubMed Web of Science ®Google Scholar
• Kasi PM, Tawbi HA, Oddis CV, et al. Clinical review: serious adverse events associated with the use of rituximab - a critical care perspective. Crit Care. 2012;16(4):231.
   PubMed Web of Science ®Google Scholar
• Mojs E, Warchoł-Biedermann K, Samborski W. What do we know about psychological outcomes of lymphoma in adults? Eur Psychol. 2017;22(2):121–131.
   Web of Science ®Google Scholar
• Byford S, Torgerson DJ, Raftery J. Economic note: cost of illness studies. BMJ. 2000;320(7245):1335.
   PubMed Web of Science ®Google Scholar
• Koopmanschap MA. Cost-of-illness studies. Useful for health policy? Pharm Eco. 1998;14(2):143–148.
   PubMed Web of Science ®Google Scholar
• Romio S, Sturkenboom M, Corrao G. Real-world data from the health decision maker perspective. What are we talking about? Epidemiol Biostatistics Pub Health. 2013;10:3.
   Google Scholar
• Wang HI, Roman E, Crouch S, et al. A generic model for follicular lymphoma: predicting cost, life expectancy, and quality-adjusted-life-year using UK population-based observational data. Value Health. 2018;21(10):1176–1185.
   PubMed Web of Science ®Google Scholar
• Morrison VA, Bell JA, Hamilton L, et al. Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA. Future Oncol. 2018;14(25):2627–2642.
   PubMed Web of Science ®Google Scholar
• Shao C, Liu J, Zhou W, et al. Treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory Hodgkin lymphoma treated with brentuximab vedotin. Leuk Lymphoma. 2018;60(4):947–954.
   PubMed Web of Science ®Google Scholar
• Bonafede M, Feliciano J, Cai Q, et al. Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failure. CEOR. 2018;10:629–641.
   Google Scholar
• Maziarz RT, Hao Y, Guerin A, et al. Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2018;59(5):1133–1142.
   PubMed Web of Science ®Google Scholar
• Khor S, Beca J, Krahn M, et al. Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis. BMC Cancer. 2014;14(1):586.
   PubMedGoogle Scholar
• Best JH, Hornberger J, Proctor SJ, et al. Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma. Value Health. 2005;8(4):462–470.
   PubMed Web of Science ®Google Scholar
• Deconinck E, Miadi-Fargier H, Pen CL, et al. Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation. Pharmacoeconomics. 2010;28(1):35–46.
   PubMed Web of Science ®Google Scholar
• Bezin J, Duong M, Lassalle R, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(8):954–962.
   PubMed Web of Science ®Google Scholar
• Moulis G, Lapeyre-Mestre M, Palmaro A, et al. French health insurance databases: what interest for medical research? Rev Med Interne. 2015;36(6):411–417.
   PubMed Web of Science ®Google Scholar
• Conte C, Palmaro A, Grosclaude P, et al. A novel approach for medical research on lymphomas: a study validation of claims-based algorithms to identify incident cases. Medicine. 2018;97(2):e9418.
   PubMed Web of Science ®Google Scholar
• Anatomical Therapeutic Chemical Classification. [cited 2017 Jun 1]. Available at: http://ec.europa.eu/health/documents/community-register/html/atc.htm.
   Google Scholar
• Organisation for Economic Co-operation and Development (OECD). Anon. 4. PPPs and exchange rates. [cited 2017 Jun 1]. Available at: https://stats.oecd.org/Index.aspx?DataSetCode=SNA_TABLE4.
   Google Scholar
• Bannay A, Chaignot C, Blotière PO, et al. The best use of the charlson comorbidity index with electronic health care database to predict mortality. Med Care. 2016;54(2):188–194.
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomized controlled trial. Lancet. 2011;377(9759):42–51.
   PubMed Web of Science ®Google Scholar
• Brigitte D, Carine M. ÉCONOMIE ET STATISTIQUE N 455–456, 2012. Comment évaluer la productivité et l’efficacité des hôpitaux publics et privés? Les enjeux de la convergence tarifaire [ECONOMICS AND STATISTICS N°455 -456, 2012. How to assess the productivity and efficiency of public and private hospitals? The challenges of price convergence].
   Google Scholar
• Tabernero J, Vyas M, Giuliani R, et al. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. ESMO Open. 2017;1(6):e000142.
   PubMed Web of Science ®Google Scholar
• Ronnebaum S, Atzinger C. Enhancing Biosimilar Adoption With Real-World Evidence. Health Economics and Outcomes Research (HEOR) article. July/August 2018. Value & Outcomes Spotlight.
   Google Scholar
• Dolan C. Opportunities and challenges in biosimilar uptake in oncology. Am J Manag Care. 2018;24(11):S237–S243.
   PubMed Web of Science ®Google Scholar
• Simoens S, Jacobs I, Popovian R, et al. Assessing the value of biosimilars: a review of the role of budget impact analysis. Pharmaco Eco. 2017;35(10):1047–1062.
   PubMed Web of Science ®Google Scholar
• Rognoni C, Bertolani A, Jommi C. Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives. Global Regional Health Technol Assessment. 2018;20:1–11.
   Web of Science ®Google Scholar
• French National Agency for Medicines and Health Products Safety. 2016. État des lieux sur les medicaments biosimilaires [State of art about biosimilar medication] Available from: https://www.ansm.sante.fr/content/download/88209/1110173/version/1/file/Rapport-biosimilaires-2mai2016.pdf.
   Google Scholar
• Compaci G, Ysebaert L, Obéric L, et al. Effectiveness of telephone support during chemotherapy in patients with diffuse large B cell lymphoma: the Ambulatory Medical Assistance (AMA) experience. Int J Nurs Stud. 2011;48(8):926–932.
   PubMed Web of Science ®Google Scholar
• Sirintrapun SJ, Lopez AM. Telemedicine in cancer care. Am Soc Clin Oncol Educ Book. 2018;38:540–545.
   PubMedGoogle Scholar
• World Health Organization. Therapeutic Patient Education Continuing Education Programmes for Health Care Providers in the Field of Prevention of Chronic Diseases. 1998.
   Google Scholar
• Kamal KM, Covvey JR, Dashputre A, et al. A systematic review of the effect of cancer treatment on work productivity of patients and caregivers. JMCP. 2017; 23(2):136–162.
   PubMed Web of Science ®Google Scholar
• Davies A, Berge C, Boehnke A, et al. Subcutaneous rituximab for the treatment of B-Cell hematologic malignancies: a review of the scientific rationale and clinical development. Adv Ther. 2017;34(10):2210–2231.
   PubMed Web of Science ®Google Scholar
• Laurent C, Baron M, Amara N, et al. Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French lymphopath network. JCO. 2017;35(18):2008–2017.
   PubMed Web of Science ®Google Scholar
• Stienen JJ, Hermens RP, Wennekes L, PEARL study group, et al. Variation in guideline adherence in non-Hodgkin's lymphoma care: impact of patient and hospital characteristics. BMC Cancer. 2015;15(1):578.
   PubMedGoogle Scholar
• Feldman T, Gromko L, Protomastro EA, et al. Relapses of diffuse large B cell lymphoma in rituximab era are limited to the first two years after frontline therapy. Blood. 2014;124(21):1307.
   Web of Science ®Google Scholar
• Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. JCO. 2015;33(23):2516–2522.
   PubMed Web of Science ®Google Scholar
• Montanari F, Diefenbach C. Relapsed Hodgkin lymphoma: management strategies. Curr Hematol Malig Rep. 2014;9(3):284.
   PubMed Web of Science ®Google Scholar